Vasopressin (Argipressin)

Generic name
Vasopressin (Argipressin)
Brand name
ATC Code
H01BA01
Compare …

Vasopressin (Argipressin)

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

Specific pharmacokinetic parameters are not available for children.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Hypotension and vasodilatory shock with refractory hypotension
  • Intravenous
    • Gestational age < 37 weeks
      • 0.01 - 0.12 IU/kg/hour, continuous infusion. Corresponding to 0,17-2 milli-IU/kg/MIN.
        • Titrate dose to effect
        • Dose reductions of concomittant vasopressors may be needed
    • Term neonate
      • 0.01 - 0.12 IU/kg/hour, continuous infusion. Corresponding to 0,17- 2 milli-IU/kg/MIN.
        • Titrate dose to effect.
        • Dose reductions of concomittant vasopressors may be needed
    • 1 month up to 18 years
      • 0.01 - 0.12 IU/kg/hour, continuous infusion. Corresponding to 0,17- 2 milli-IU/kg/MIN.
        • Titrate dose to effect.
        • Dose reductions of concomittant vasopressors may be needed

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Reduction in platelet counts [Jerath et al. 2008]

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

POSTERIOR PITUITARY LOBE HORMONES

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Vasopressin and analogues
H01BA02

References

  1. Ikegami, H., at al., Low-dose vasopressin infusion therapy for refractory hypotension in ELBW infants, Pediatr Int, 2010, 52 (3), 368-73
  2. Rios, DR., et al, Vasopressin versus dopamine for treatment of hypotension in extremely low birth weight infants: a randomized, blinded pilot study, J Pediatr, 2015, 166 (4), 850-5
  3. Agrawal, A., et al, Intravenous arginine vasopressin infusion in refractory vasodilatory shock: a clinical study, Indian J Pediatr, 2012, 79 (4), 488-93
  4. Bidegain, MR., et al., Vasopressin for refractory hypotension in extremely low birth weight infants, J Pediatr, 2010, 157 (3), 502-4
  5. Jerath, N., et al., Clinical impact of vasopressin infusion on hemodynamics, liver and renal function in pediatric patients, Intensive Care Med, 2008, 34 (7), 1274-80
  6. Choong, K., et al, Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial, Am J Resp Crit Care Med, 2009, 180 (7), 632-9
  7. Meyer, S., et al, Effects of vasopressin on renal function in children with severe forms of shock, Crit Care Med, 2008, 36 (10), 2959

Changes

Therapeutic Drug Monitoring


Overdose